Overall survival | |||||||||
---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | |||||||
HR | (95%CI) | p= | HR | (95%CI) | p= | HR | (95%CI) | p= | |
PSA,ng/ml | |||||||||
≤10ng/ml | 1.0 | 1.0 | 1.0 | ||||||
>10ng/ml | 0.49 | (0.13-1.83) | 0.3 | 0.45 | (0.12-1.74) | 0.2 | 0.45 | (0.12-1.74) | 0.2 |
Extra-prostatic extension | |||||||||
Yes | 1.0 | 1.0 | 1.0 | ||||||
No | 3.34 | (0.71-15.66) | 0.1 | 3.75 | (0.79-17.88) | 0.1 | 3.52 | (0.74-16.77) | 0.1 |
Pelvic nodes involved | |||||||||
N0 | 1.0 | 1.0 | 1.0 | ||||||
N+ | 1.72 | (0.50-5.88) | 0.4 | 1.45 | (0.43-4.93) | 0.5 | 1.41 | (0.41-4.79) | 0.6 |
Surgical margins involved | |||||||||
No | 1.0 | 1.0 | 1.0 | ||||||
Yes | 1.42 | (0.46-4.38) | 0.5 | 1.36 | (0.46-3.99) | 0.6 | 1.31 | (0.44-3.89) | 0.6 |
Seminal vesicles involved | |||||||||
No | 1.0 | 1.0 | 1.0 | ||||||
Yes | 1.41 | (0.50-3.97) | 0.5 | 1.06 | (0.37-3.05) | 0.9 | 1.12 | (0.38-3.20) | 0.8 |
Gleason score | |||||||||
<7 | 1.0 | ||||||||
≥7 | 2.19 | (0.56-8.62) | 0.3 | ||||||
Gleason score | |||||||||
≤7 | 1.0 | ||||||||
>7 | 2.75 | (0.90-8.42) | 0.08 | ||||||
Gleason score | |||||||||
<7 | 1.0 | 0.2 | |||||||
=7 | 1.49 | (0.33-6.81) | 0.6 | ||||||
>7 | 3.56 | (0.78-16.20) | 0.1 | ||||||
Stromal -Epithelial IRS Score | |||||||||
=12/≤2 | 1.0 | 0.01 | 1.0 | 0.01 | 1.0 | 0.01 | |||
<12/≤2 | 0.13 | (0.04-0.44) | 0.001 | 0.14 | (0.04-0.46) | 0.001 | 0.14 | (0.04-0.45) | 0.001 |
=12/>2 | 0.19 | (0.02-1.37) | 0.1 | 0.21 | (0.03-1.58) | 0.1 | 0.20 | (0.02-1.53) | 0.1 |
<12/>2 | 0.12 | (0.01-1.32) | 0.08 | 0.12 | (0.01-1.43) | 0.09 | 0.11 | (0.01-1.37) | 0.09 |